All news

Sunshine Biopharma closes $6 million public offering

Alpha Vantage · The Globe and Mail · · AI-summarised by FinFlash

Sunshine Biopharma (SBFM) closed a public offering raising roughly $6 million in gross proceeds on October 9, 2026. The deal comprised common and pre-funded units, each paired with Series D warrants, priced at $0.55 and $0.54999. Proceeds fund general corporate purposes, working capital and drug development. The raise dilutes existing shareholders while extending the company's cash runway.

Read original source

SBFM company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.